The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas.
MetadataShow full item record
AbstractNon-small-cell lung cancer (NSCLC) subtyping has recently been a key factor in determining patient management with novel drugs. In addition, the identification of distinct oncogenic driver mutations frequently associated with NSCLC histotype and coupled to the clinical responses to targeted therapies have revolutionized the impact of histologic type and molecular biomarkers in lung cancer. Several molecular alterations involving different genes (EGFR, KRAS, ALK, BRAF, and HER2) seem to have a remarkable predilection for adenocarcinoma and specific inhibitors of EGFR and ALK are now available for patients with adenocarcinoma harboring the relevant gene alterations. The efficacy of histology-based and molecular-targeted therapies had a deep impact in (1) re-defining classification of lung cancer (particularly adenocarcinomas) and (2) routine clinical practice of pathologists involved in optimization of handling of tissue samples in order to guarantee NSCLC subtyping with the help of immunohistochemistry and adequately preserve tumor cells for molecular analysis. In agreement with the modern multidisciplinary approach to lung cancer, we reviewed here the diagnostic and predictive value of molecular biomarkers according to the clinical, pathologic, and molecular biologist viewpoints.
CitationThe role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. 2013, 30 (4):298-312 Semin Diagn Pathol
JournalSeminars in Diagnostic Pathology
- Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer.
- Authors: Kobayashi M, Sonobe M, Takahashi T, Yoshizawa A, Ishikawa M, Kikuchi R, Okubo K, Huang CL, Date H
- Issue date: 2011 Dec
- The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.
- Authors: Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M, University of Hong Kong Lung Cancer Study Group.
- Issue date: 2009 Apr 15
- Biomarkers for personalized oncology: recent advances and future challenges.
- Authors: Kalia M
- Issue date: 2015 Mar
- Genetics and biomarkers in personalisation of lung cancer treatment.
- Authors: Rosell R, Bivona TG, Karachaliou N
- Issue date: 2013 Aug 24
- What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
- Authors: Cooper WA, O'toole S, Boyer M, Horvath L, Mahar A
- Issue date: 2011 Feb